Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xlife Sciences AGXSWX:XLS -0.88%48 Intrinsic Value: Projected FCF is CHF28.84 as of Aug. 03, 2026, which is 100% below its 10-year median of 0.84. GuruFocus rates XSWX:XLS with a GF Score™ of 48/100 and a GF Value™ of CHF7.13 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 257 Biotechnology companies, Xlife Sciences AG ranks better than 90.66% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-03), Xlife Sciences AG's Intrinsic Value: Projected FCF is CHF28.84. The stock price of Xlife Sciences AG is CHF16.85. Therefore, Xlife Sciences AG's Price-to-Intrinsic-Value-Projected-FCF of today is 0.6.
The historical rank and industry rank for Xlife Sciences AG's Intrinsic Value: Projected FCF or its related term are showing as below:
XSWX:XLS'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.57 Med: 0.84 Max: 0.86
Current: 0.58
During the past 8 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Xlife Sciences AG was 0.86. The lowest was 0.57. And the median was 0.84.
XSWX:XLS's Price-to-Projected-FCF is ranked better than 90.66% of 257
companies
in the Biotechnology industry
Industry Median: 1.98
vs XSWX:XLS: 0.58
Xlife Sciences AG (XSWX:XLS) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Xlife Sciences AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
16.85
/
28.840816490155
=
0.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG Intrinsic Value: Projected FCF Related Terms
Xlife Sciences AG Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG Intrinsic Value: Projected FCF Chart
XSWX:XLS vs VRTX, REGN, RVMD: Intrinsic Value: Projected FCF Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Price-to-Projected-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Price-to-Projected-FCF falls into.
Xlife Sciences AG Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of CHF28.84 mean?
Xlife Sciences AG (XSWX:XLS) has a Intrinsic Value: Projected FCF of CHF28.84 as of Aug. 03, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Xlife Sciences AG and its competitors. This is 3333% above median its historical median of 0.84. Over the past decade, Xlife Sciences AG's Intrinsic Value: Projected FCF has ranged from 0.57 to 0.86. According to the industry distribution chart, Xlife Sciences AG ranks #24 out of 257 companies in the Biotechnology industry, placing it in the top 9.3%.
Is Xlife Sciences AG's Intrinsic Value: Projected FCF too high?
Xlife Sciences AG's current Intrinsic Value: Projected FCF of CHF28.84 is 3333% above median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 0.86. Based on the distribution chart, Xlife Sciences AG ranks #24 out of 257 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Intrinsic Value: Projected FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #24 out of 257 companies for Intrinsic Value: Projected FCF. This places Xlife Sciences AG in the top 9% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.98. Historically, Xlife Sciences AG's own Intrinsic Value: Projected FCF has ranged from 0.57 to 0.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Biotechnology company?
The median Intrinsic Value: Projected FCF among Biotechnology companies is 1.98, based on 257 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Intrinsic Value: Projected FCF is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Intrinsic Value: Projected FCF is CHF28.84, which is 3333% above median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.13, compared to a current price of CHF16.85 — trading 136.3% above its estimated fair value. The current Intrinsic Value: Projected FCF is CHF28.84, which is 3333% above median its 10-year median of 0.84. Xlife Sciences AG's overall GF Score™ is 48/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Intrinsic Value: Projected FCF is CHF28.84 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF16.85 is trading 136.3% above its estimated GF Value™ of CHF7.13.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Intrinsic Value: Projected FCF: CHF28.84 (3333% above median its 10-year median of 0.84)
GF Value™: CHF7.13 vs. price of CHF16.85 (136.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
48GF Score
Get the complete analysis for XSWX:XLS
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
